Download PDF
Facial Plast Surg 2012; 28(06): 575-583
DOI: 10.1055/s-0032-1329932
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medical Management of Vascular Anomalies

Francine Blei
1   Vascular Birthmark Institute of New York, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2012 (online)

Also available at
    Permissions and Reprints

Abstract

The term “vascular anomalies” embraces a spectrum of medical conditions characterized by abnormal growth or development of blood and/or lymphatic vessels. Patient management is frequently provided in a multidisciplinary team approach, as there are many facets to evaluation and treatment. Clinical and basic research during the past decade has enhanced our knowledge, providing insight into possible etiologies, associated genetic mutations, cellular mechanisms modulating the development, and natural history of these disorders. Concomitantly, new therapeutic agents have been identified, which has transformed patient management. In this review, a brief overview of the field including an update in basic research is presented, followed by a discussion of current therapies and their purported mechanism of action.

Keywords

vascular anomalies - hemangioma - vascular malformation
 

  • References

  • 1 Shirazi F, Cohen C, Fried L, Arbiser JL. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 2007; 5: 233-236
    CrossrefPubMedGoogle Scholar
  • 2 Adepoju O, Wong A, Kitajewski A , et al. Expression of HES and HEY genes in infantile hemangiomas. Vasc Cell 2011; 3: 19
    CrossrefPubMedGoogle Scholar
  • 3 Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis 2009; 12: 197-207
    CrossrefPubMedGoogle Scholar
  • 4 Boscolo E, Mulliken JB, Bischoff J. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2011; 179: 2266-2277
    CrossrefPubMedGoogle Scholar
  • 5 Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010; 13: 327-335
    CrossrefPubMedGoogle Scholar
  • 6 Greenberger S, Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med 2011; 1: a006460
    CrossrefPubMedGoogle Scholar
  • 7 Greenberger S, Yuan S, Walsh LA , et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131: 2467-2476
    CrossrefPubMedGoogle Scholar
  • 8 Boye E, Olsen BR. Signaling mechanisms in infantile hemangioma. Curr Opin Hematol 2009; 16: 202-208
    CrossrefPubMedGoogle Scholar
  • 9 Jinnin M, Ishihara T, Boye E, Olsen BR. Recent progress in studies of infantile hemangioma. J Dermatol 2010; 37: 283-298
    CrossrefPubMedGoogle Scholar
  • 10 Ostergaard P, Simpson MA, Mendola A , et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 2012; 90: 356-362
    CrossrefPubMedGoogle Scholar
  • 11 Pansuriya TC, van Eijk R, d'Adamo P , et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256-1261
    CrossrefPubMedGoogle Scholar
  • 12 Thiex R, Mulliken JB, Revencu N , et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. AJNR Am J Neuroradiol 2010; 31: 775-779
    CrossrefPubMedGoogle Scholar
  • 13 Boon LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg 2011; 38: 7-19
    CrossrefPubMedGoogle Scholar
  • 14 Wooderchak-Donahue W, Stevenson DA, McDonald J , et al. Rasa1 analysis: Clinical and molecular findings in a series of consecutive cases. Eur J Med Genet 2011; (Dec) 8
    PubMedGoogle Scholar
  • 15 Alomari AI. Diversion venography—a modified technique in Klippel-Trenaunay syndrome: initial experience. J Vasc Interv Radiol 2010; 21: 685-689
    CrossrefPubMedGoogle Scholar
  • 16 Hernandez-Martin S, Lopez-Gutierrez JC, Lopez-Fernandez S , et al. Brain perfusion SPECT in patients with PHACES syndrome under propranolol treatment. Eur J Pediatr Surg [et al] = . Z Kinderchir 2011; (Nov) 3
    PubMedGoogle Scholar
  • 17 Lohrmann C, Foeldi E, Langer M. Assessment of the lymphatic system in patients with diffuse lymphangiomatosis by magnetic resonance imaging. Eur J Radiol 2011; 80: 576-581
    CrossrefPubMedGoogle Scholar
  • 18 Maus EA, Tan IC, Rasmussen JC , et al. Near-infrared fluorescence imaging of lymphatics in head and neck lymphedema. Head Neck 2012; 34: 448-453
    CrossrefPubMedGoogle Scholar
  • 19 Léauté-Labrèze C, Prey S, Ezzedine K. Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol 2011; 25: 1245-1253
    CrossrefPubMedGoogle Scholar
  • 20 Drolet BA, Swanson EA, Frieden IJ. Hemangioma Investigator Group. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008; 153: 712-715 , 715, e1
    CrossrefPubMedGoogle Scholar
  • 21 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651
    CrossrefPubMedGoogle Scholar
  • 22 Hammill AM, Wentzel M, Gupta A , et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57: 1018-1024
    CrossrefPubMedGoogle Scholar
  • 23 McCuaig CC, Dubois J, Powell J , et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009; 26: 203-212
    CrossrefPubMedGoogle Scholar
  • 24 Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146: 564-565
    CrossrefPubMedGoogle Scholar
  • 25 Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med 2012; 366: 384-386
    CrossrefPubMedGoogle Scholar
  • 26 Grunewald TG, Damke L, Maschan M , et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol 2010; 21: 1733-1734
    CrossrefPubMedGoogle Scholar
  • 27 Baselga E, Cordisco MR, Garzon M, Lee MT, Alomar A, Blei F. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol 2008; 158: 1363-1370
    CrossrefPubMedGoogle Scholar
  • 28 North PE, Waner M, Mizeracki A , et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137: 559-570
    PubMedGoogle Scholar
  • 29 Metry D, Heyer G, Hess C , et al; PHACE Syndrome Research Conference. Consensus statement on diagnostic criteria for phace syndrome. Pediatrics 2009; 124: 1447-1456
    CrossrefPubMedGoogle Scholar
  • 30 Stockman A, Boralevi F, Taïeb A, Léauté-Labrèze C. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214: 40-45
    CrossrefPubMedGoogle Scholar
  • 31 Iacobas I, Burrows PE, Frieden IJ , et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157: 795-801 , e1–e7
    CrossrefPubMedGoogle Scholar
  • 32 Alomari AI. CLOVE(S) syndrome: expanding the acronym. Am J Med Genet A 2009; 149A: 294 ; author reply 295
    CrossrefPubMedGoogle Scholar
  • 33 Faughnan ME, Palda VA, Garcia-Tsao G , et al; HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48: 73-87
    CrossrefPubMedGoogle Scholar
  • 34 Radhakrishnan K, Rockson SG. Gorham's disease: an osseous disease of lymphangiogenesis?. Ann N Y Acad Sci 2008; 1131: 203-205
    CrossrefPubMedGoogle Scholar
  • 35 Tan WH, Baris HN, Burrows PE , et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007; 44: 594-602
    CrossrefPubMedGoogle Scholar
  • 36 Kasabach H, Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child 1940; 59: 1063
    PubMedGoogle Scholar
  • 37 Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377-1386
    CrossrefPubMedGoogle Scholar
  • 38 Enjolras O, Wassef M, Mazoyer E , et al. Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas. J Pediatr 1997; 130: 631-640
    PubMedGoogle Scholar
  • 39 Gruman A, Liang MG, Mulliken JB , et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 2005; 52: 616-622
    CrossrefPubMedGoogle Scholar
  • 40 Kauvar AN, Wang RS. Laser treatment of cutaneous vascular anomalies. Lymphat Res Biol 2004; 2: 38-50
    CrossrefPubMedGoogle Scholar
  • 41 Sun ZY, Yang L, Yi CG , et al. Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. Med Hypotheses 2008; 71: 286-292
    CrossrefPubMedGoogle Scholar
  • 42 Chang EI, Chang EI, Thangarajah H, Hamou C, Gurtner GC. Hypoxia, hormones, and endothelial progenitor cells in hemangioma. Lymphat Res Biol 2007; 5: 237-243
    CrossrefPubMedGoogle Scholar
  • 43 Xiao X, Liu J, Sheng M. Synergistic effect of estrogen and VEGF on the proliferation of hemangioma vascular endothelial cells. J Pediatr Surg 2004; 39: 1107-1110
    CrossrefPubMedGoogle Scholar
  • 44 Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg 1984; 73: 359-370
    PubMedGoogle Scholar
  • 45 Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-752
    CrossrefPubMedGoogle Scholar
  • 46 Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103: 1373-1375
    PubMedGoogle Scholar
  • 47 Yu Y, Fuhr J, Boye E , et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells 2006; 24: 1605-1612
    CrossrefPubMedGoogle Scholar
  • 48 Dosanjh A, Chang J, Bresnick S , et al. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000; 27: 441-450
    CrossrefPubMedGoogle Scholar
  • 49 Hansen SL, Dosanjh A, Young DM, Boudreau N, Hoffman WY. Hemangiomas and homeobox gene expression. J Craniofac Surg 2006; 17: 767-771
    CrossrefPubMedGoogle Scholar
  • 50 Kageyama R, Ohtsuka T, Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007; 134: 1243-1251
    CrossrefPubMedGoogle Scholar
  • 51 Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 2011; 64: 759-765
    CrossrefPubMedGoogle Scholar
  • 52 Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119: 284-288
    CrossrefPubMedGoogle Scholar
  • 53 Pau H, Carney AS, Walker R, Murty GE. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol Allied Sci 2000; 25: 547-550
    PubMedGoogle Scholar
  • 54 Dresse MF, David M, Hume H , et al. Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol 1991; 8: 329-334
    CrossrefPubMedGoogle Scholar
  • 55 Ortel TL, Onorato JJ, Bedrosian CL, Kaufman RE. Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome. Am J Hematol 1988; 29: 44-48
    CrossrefPubMedGoogle Scholar
  • 56 Fernandez-Pineda I, Lopez-Gutierrez JC, Ramirez G, Marquez C. Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach-Merritt phenomenon associated with vascular tumors. Pediatr Hematol Oncol 2010; 27: 641-645
    CrossrefPubMedGoogle Scholar
  • 57 Zimmermann AP, Wiegand S, Werner JA, Eivazi B. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010; 74: 338-342
    CrossrefPubMedGoogle Scholar
  • 58 Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274
    CrossrefPubMedGoogle Scholar
  • 59 Trautmann K, Bethke A, Ehninger G, Folprecht G. Bevacizumab for recurrent hemangioendothelioma. Acta Oncol 2011; 50: 153-154
    CrossrefPubMedGoogle Scholar
  • 60 Fleagle JM, Bobba RK, Kardinal CG, Freter CE. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. Am J Med Sci 2012; 343: 249-251
    CrossrefPubMedGoogle Scholar
  • 61 Kline RM, Buck LM. Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia. Pediatr Blood Cancer 2009; 52: 534-536
    CrossrefPubMedGoogle Scholar
  • 62 Héritier S, Le Merrer M, Jaubert F , et al. Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988–2009. Orphanet J Rare Dis 2010; 5: 3
    CrossrefPubMedGoogle Scholar
  • 63 Klement G, Cervi D, Orbach D , et al. Pten associated lesions regress in response to the antiangiogenic therapy with thalidomide/celebrex. Presented at: 17th International Workshop of ISSVA; June 20–24, 2008; Boston, MA
    PubMedGoogle Scholar
  • 64 Perry BN, Govindarajan B, Bhandarkar SS , et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 2006; 126: 2316-2322
    CrossrefPubMedGoogle Scholar
  • 65 Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007; 56: 63-68
    CrossrefPubMedGoogle Scholar
  • 66 Jiang C, Hu X, Ma G , et al. A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. Pediatr Dermatol 2011; 28: 259-266
    CrossrefPubMedGoogle Scholar
  • 67 Tremaine AM, Armstrong J, Huang YC , et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol 2012; (Jan) 13
    PubMedGoogle Scholar
  • 68 White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197-1200
    CrossrefPubMedGoogle Scholar
  • 69 Gonzalez D, Elizondo BJ, Haslag S , et al. Chronic subcutaneous octreotide decreases gastrointestinal blood loss in blue rubber-bleb nevus syndrome. J Pediatr Gastroenterol Nutr 2001; 33: 183-188
    CrossrefPubMedGoogle Scholar
  • 70 Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-1436
    CrossrefPubMedGoogle Scholar
  • 71 Suver DW, Perkins JA, Manning SC. Somatostatin treatment of massive lymphorrhea following excision of a lymphatic malformation. Int J Pediatr Otorhinolaryngol 2004; 68: 845-850
    CrossrefPubMedGoogle Scholar
  • 72 Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabéu C, Botella LM. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534
    Article in Thieme ConnectPubMedGoogle Scholar
  • 73 Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993; 155: 568-578
    CrossrefPubMedGoogle Scholar
  • 74 Tan HH, Ge ZZ, Gao YJ , et al. The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. J Dig Dis 2011; 12: 349-356
    CrossrefPubMedGoogle Scholar
  • 75 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13: 5979-5984
    CrossrefPubMedGoogle Scholar
  • 76 Lebrin F, Srun S, Raymond K , et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428
    CrossrefPubMedGoogle Scholar
  • 77 Thomson K, Pinnock R, Teague L, Johnson R, Manikkam N, Drake R. Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience. N Z Med J 2007; 120: U2418
    PubMedGoogle Scholar
  • 78 Haisley-Royster C, Enjolras O, Frieden IJ , et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 2002; 24: 459-462
    CrossrefPubMedGoogle Scholar
  • 79 Hochman M, Adams DM, Reeves TD. Current knowledge and management of vascular anomalies: I. Hemangiomas. Arch Facial Plast Surg 2011; 13: 145-151
    CrossrefPubMedGoogle Scholar
  • 80 Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010; 29: 106-114
    CrossrefPubMedGoogle Scholar
  • 81 Buckmiller LM, Richter GT, Suen JY. Diagnosis and management of hemangiomas and vascular malformations of the head and neck. Oral Dis 2010; 16: 405-418
    CrossrefPubMedGoogle Scholar
  • 82 Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus 1994; 31: 153-156
    PubMedGoogle Scholar
  • 83 Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005; 52: 281-286
    CrossrefPubMedGoogle Scholar
  • 84 Buckmiller LM, Francis CL, Glade RS. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol 2008; 72: 81-87
    CrossrefPubMedGoogle Scholar
  • 85 Pope E, Krafchik BR, Macarthur C , et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics 2007; 119: e1239-e1247
    CrossrefPubMedGoogle Scholar
  • 86 Greene AK. Corticosteroid treatment for problematic infantile hemangioma: evidence does not support an increased risk for cerebral palsy. Pediatrics 2008; 121: 1251-1252
    CrossrefPubMedGoogle Scholar
  • 87 Greene AK. Systemic corticosteroid is effective and safe treatment for problematic infantile hemangioma. Pediatr Dermatol 2010; 27: 322-323
    CrossrefPubMedGoogle Scholar
  • 88 Chianese J, Blei F. Corticosteroid toxicity in infants treated for endangering hemangiomas: Experience and guidelines for monitoring. Int Pediatr 1999; 14: 146-153
    PubMedGoogle Scholar
  • 89 Ray WZ, Lee A, Blackburn SL, Lueder GT, Leonard JR. Pseudotumor cerebri following tapered corticosteroid treatment in an 8-month-old infant. J Neurosurg Pediatr 2008; 1: 88-90
    CrossrefPubMedGoogle Scholar
  • 90 Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 2007; 143: 1224-1225
    PubMedGoogle Scholar
  • 91 Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004; 79: 243-245
    CrossrefPubMedGoogle Scholar
  • 92 Al-Mahdi H. Iris depigmentation: an unusual complication of intralesional corticosteroid injection for capillary hemangioma. Middle East Afr J Ophthalmol 2010; 17: 100-102
    PubMedGoogle Scholar
  • 93 Deboer MD, Boston BA. Failure-to-thrive in an infant following injection of capillary hemangioma with triamcinolone acetonide. Clin Pediatr (Phila) 2008; 47: 296-299
    CrossrefPubMedGoogle Scholar
  • 94 Goyal R, Watts P, Lane CM, Beck L, Gregory JW. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004; 111: 389-395
    CrossrefPubMedGoogle Scholar
  • 95 Kushner BJ, Lemke BN. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy. J Pediatr Ophthalmol Strabismus 1993; 30: 397-399
    PubMedGoogle Scholar
  • 96 Ang LP, Lee MW, Seah LL, Cheong P, Rootman J. Orbital cellulitis following intralesional corticosteroid injection for periocular capillary haemangioma. Eye (Lond) 2007; 21: 999-1001
    PubMedGoogle Scholar
  • 97 Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-e266
    CrossrefPubMedGoogle Scholar
  • 98 Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol 2011; 120: 686-695
    PubMedGoogle Scholar
  • 99 Truong MT, Perkins JA, Messner AH, Chang KW. Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. Int J Pediatr Otorhinolaryngol 2010; 74: 1043-1048
    CrossrefPubMedGoogle Scholar
  • 100 Leboulanger N, Fayoux P, Teissier N , et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010; 74: 1254-1257
    CrossrefPubMedGoogle Scholar
  • 101 Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010; 14: 251-256
    PubMedGoogle Scholar
  • 102 Rosbe KW, Suh KY, Meyer AK, Maguiness SM, Frieden IJ. Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg 2010; 136: 658-665
    CrossrefPubMedGoogle Scholar
  • 103 Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2010; (Jul) 6
    PubMedGoogle Scholar
  • 104 Mazereeuw-Hautier J, Hoeger PH, Benlahrech S , et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010; 157: 340-342
    CrossrefPubMedGoogle Scholar
  • 105 Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128: 255-256
    CrossrefPubMedGoogle Scholar
  • 106 Cante V, Pham-Ledard A, Imbert E, Ezzedine K, Léauté-Labrèze C. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed 2012; 97: F155-F156
    CrossrefPubMedGoogle Scholar
  • 107 Chakkittakandiyil A, Phillips R, Frieden IJ , et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29: 28-31
    CrossrefPubMedGoogle Scholar
  • 108 Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011; (Dec) 16
    PubMedGoogle Scholar
  • 109 Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol 2010; 27: 195-196
    CrossrefPubMedGoogle Scholar
  • 110 Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011; 28: 169-171
    CrossrefPubMedGoogle Scholar
  • 111 Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146: 775-778
    CrossrefPubMedGoogle Scholar
  • 112 Allford MA, Brown JL. Case report: intraoperative hypoglycaemia in a child treated with propranolol following a short preoperative fast. Eur J Anaesthesiol 2011; 28: 71-72
    PubMedGoogle Scholar
  • 113 Naouri M, Schill T, Maruani A, Bross F, Lorette G, Rossler J. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol 2010; 24: 1109-1112
    PubMedGoogle Scholar
  • 114 Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. Pediatrics 2011; 127: e772-e776
    CrossrefPubMedGoogle Scholar
  • 115 Thomas J, Kumar P, Kumar DD. Ulcerated infantile haemangioma of leg successfully treated with propranolol. J Cutan Aesthet Surg 2011; 4: 211-213
    CrossrefPubMedGoogle Scholar
  • 116 Missoi TG, Lueder GT, Gilbertson K, Bayliss SJ. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol 2011; 129: 899-903
    CrossrefPubMedGoogle Scholar
  • 117 Sciveres M, Marrone G, Pipitone S , et al. Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload. J Pediatr Gastroenterol Nutr 2011; 53: 693-695
    PubMedGoogle Scholar
  • 118 Chamlin SL, Haggstrom AN, Drolet BA , et al. Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007; 151: 684-689 , 689, e1
    PubMedGoogle Scholar
  • 119 Naouri M, Schill T, Maruani A, Bross F, Lorette G, Rossler J. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol 2010; 24: 1109-1112
    PubMedGoogle Scholar
  • 120 Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J , et al; Groupe de Recherche Clinique en Dermatologie Pédiatrique. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64: 827-832
    CrossrefPubMedGoogle Scholar
  • 121 Kim LH, Hogeling M, Wargon O, Jiwane A, Adams S. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46: 759-763
    CrossrefPubMedGoogle Scholar
  • 122 Sugarman JL, Mauro TM, Frieden IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002; 138: 314-316
    CrossrefPubMedGoogle Scholar
  • 123 Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004; 140: 867-870
    CrossrefPubMedGoogle Scholar
  • 124 Lapidoth M, Ben-Amitai D, Bhandarkar S, Fried L, Arbiser JL. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 2009; 60: 350-351
    CrossrefPubMedGoogle Scholar
  • 125 Sans V, de la Roque ED, Berge J , et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124: e423-e431
    CrossrefPubMedGoogle Scholar
  • 126 Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274
    CrossrefPubMedGoogle Scholar
  • 127 Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208
    CrossrefPubMedGoogle Scholar
  • 128 Dai Y, Hou F, Buckmiller L , et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Arch Otolaryngol Head Neck Surg 2012; 138: 177-182
    CrossrefPubMedGoogle Scholar
  • 129 Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995; 58: 264-268
    CrossrefPubMedGoogle Scholar
  • 130 Sander T, Noll L, Zembles T , et al. Detection of cyp2c19 single nucleotide polymorphisms in patients with infantile hemangioma that predict reduced metabolism of propranolol. Presented at: 18th Congress of the International Society for the Study of Vascular Anomalies; April 21–24, 2010; Brussels, Belgium
    PubMedGoogle Scholar
  • 131 Blanchet C, Nicollas R, Bigorre M, Amedro P, Mondain M. Management of infantile subglottic hemangioma: acebutolol or propranolol?. Int J Pediatr Otorhinolaryngol 2010; 74: 959-961
    CrossrefPubMedGoogle Scholar
  • 132 Barlow CF, Priebe CJ, Mulliken JB , et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132 (3 Pt 1) 527-530
    CrossrefPubMedGoogle Scholar
  • 133 Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004; 114: 1231-1236
    CrossrefPubMedGoogle Scholar
  • 134 Chao YH, Liang DC, Chen SH, Wang LY, Yeh TC, Liu HC. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int 2009; 51: 469-473
    CrossrefPubMedGoogle Scholar
  • 135 Pérez-Valle S, Peinador M, Herraiz P, Saénz P, Montoliu G, Vento M. Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr 2010; 99: 311-315
    CrossrefPubMedGoogle Scholar
  • 136 Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010; 55: 1396-1398
    CrossrefPubMedGoogle Scholar
  • 137 Burrows PE, Mulliken JB, Fishman SJ, Klement GL, Folkman J. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J Craniofac Surg 2009; 20 (Suppl. 01) 597-602
    CrossrefPubMedGoogle Scholar
  • 138 Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011; 57: 321-323
    CrossrefPubMedGoogle Scholar
  • 139 Trenor III CC. Sirolimus for refractory vascular anomalies. Pediatr Blood Cancer 2011; 57: 904-905
    CrossrefPubMedGoogle Scholar
  • 140 Perry B, Banyard J, McLaughlin ER , et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007; 143: 504-506
    CrossrefPubMedGoogle Scholar
  • 141 Frieden IJ. Infantile hemangioma research: looking backward and forward. J Invest Dermatol 2011; 131: 2345-2348
    CrossrefPubMedGoogle Scholar